Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant

Detalles Bibliográficos
Autores principales: Dagan, Noa, Barda, Noam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420321/
https://www.ncbi.nlm.nih.gov/pubmed/36038121
http://dx.doi.org/10.1016/j.cmi.2022.08.017
_version_ 1784777365226782720
author Dagan, Noa
Barda, Noam
author_facet Dagan, Noa
Barda, Noam
author_sort Dagan, Noa
collection PubMed
description
format Online
Article
Text
id pubmed-9420321
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-94203212022-08-30 Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant Dagan, Noa Barda, Noam Clin Microbiol Infect Commentary European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022-12 2022-08-28 /pmc/articles/PMC9420321/ /pubmed/36038121 http://dx.doi.org/10.1016/j.cmi.2022.08.017 Text en © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Commentary
Dagan, Noa
Barda, Noam
Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant
title Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant
title_full Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant
title_fullStr Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant
title_full_unstemmed Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant
title_short Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant
title_sort effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mrna vaccines against the omicron variant
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420321/
https://www.ncbi.nlm.nih.gov/pubmed/36038121
http://dx.doi.org/10.1016/j.cmi.2022.08.017
work_keys_str_mv AT dagannoa effectivenessoffirstgenerationsevereacuterespiratorysyndromecoronavirus2mrnavaccinesagainsttheomicronvariant
AT bardanoam effectivenessoffirstgenerationsevereacuterespiratorysyndromecoronavirus2mrnavaccinesagainsttheomicronvariant

Ejemplares similares